Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

ChristianaCare

Shortage of Contrast for Imaging Services

Because of a global shortage of iodinated contrast material (Omnipaque) caused by temporary overseas manufacturing disruptions, ChristianaCare is taking steps to preserve supply so that it remains available for the most time-sensitive and urgent patient needs. (Learn more in our frequently asked questions.)

Omnipaque contrast is the most widely used contrast material for CT scans and radiographic examinations at ChristianaCare facilities. It is also used for cardiac imaging and interventions, and in the GI lab, Surgicenter and other settings.

The shortage is expected to last several weeks, and likely into the summer months.

Hospitals and health care organizations worldwide are managing the effects of the shortage and the impact to patient care.

ChristianaCare is making every effort to meet the needs of patients who need this product in their procedures. We are working individually with physicians to prioritize those patients with the most urgent needs.

Wherever possible, we are using alternative contrast material and limiting its use to ensure adequate supplies for time sensitive and emergent exams. It is possible that some elective procedures that use this product will need to be delayed.

ChristianaCare will continue to look for options to minimize disruptions created by the shortage, as we serve our community as expert, caring partners in health.

Learn more in our frequently asked questions (FAQs).

COVID-19: Click here for what to expect at ChristianaCare during COVID-19

Helen F. Graham Cancer Center
& Research Institute

How Cancer Research Benefits You

ChristianaCare’s cancer clinical trials program actively pursues today’s most promising studies for the prevention and treatment of cancer. When you join a cancer research study, you benefit from techniques and therapeutic advances that are at the vanguard of medical science. At the same time, you are helping to improve our knowledge in ways that will help people with cancer live longer and enjoy a better quality of life.

The Helen F. Graham Cancer Center & Research Institute enrolls seven times more patients in National Cancer Institute clinical trials than the national rate. We have received several national awards for our record-breaking success in enrolling patients in clinical trials. At any given time, we have at least 700 patients enrolled in as many as 130 different clinical trials. For our patients, this success means that they have access to the best treatments and procedures available to fight their type of cancer.

Translational research: From bench to bedside

In 2009, the Helen F. Graham Cancer Center & Research Institute expanded to include wet labs and a new home for the Center for Translational Research, a partnership that includes the University of Delaware, Nemours / A.I. du Pont Hospital for Children, Rice University / BioScience Research Collaborative and the Delaware Biotechnology Institute, among others. This partnership is a powerful link that allows physicians and scientific researchers to work side-by-side, identifying needs of individual patients at the bedside, bringing those problems to the lab to explore solutions, and then returning to the bedside where those new solutions can be used to help the patient.

Translational research studies are extending the boundaries of what we know about cancer. The Helen F. Graham Cancer Center & Research Institute is collecting human tissue samples to help scientists in their laboratories learn more about the growth and development of cancer. This expanding tissue-banking effort is one of only two such non-university-based programs in the country. Increased tissue procurement enhances the resources available for translational research studies that involve the application of basic science toward potential therapies.

Helen F. Graham Cancer Center & Research Institute
4701 Ogletown-Stanton Road, Newark, DE 19713 directions
302-623-4500